Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29175
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFriedlander M.en
dc.contributor.authorPearn A.en
dc.contributor.authorPachter N.en
dc.contributor.authorEbzery C.en
dc.contributor.authorPoplawski N.en
dc.contributor.authorTucker K.M.en
dc.contributor.authorGleeson M.en
dc.contributor.authorKentwell M.en
dc.contributor.authorMeiser B.en
dc.contributor.authorDo J.en
dc.contributor.authorNevin S.en
dc.contributor.authorTaylor N.en
dc.contributor.authorBarlow-Stewart K.en
dc.contributor.authorKirk J.en
dc.contributor.authorJames P.en
dc.contributor.authorScott C.L.en
dc.contributor.authorWilliams R.en
dc.contributor.authorGamet K.en
dc.contributor.authorBurke J.en
dc.contributor.authorMurphy M.en
dc.contributor.authorAntill Y.C.en
dc.date.accessioned2021-05-14T09:50:54Zen
dc.date.available2021-05-14T09:50:54Zen
dc.date.copyright2020en
dc.date.created20200819en
dc.date.issued2020-08-19en
dc.identifier.citationGynecologic Oncology. 158 (2) (pp 431-439), 2020. Date of Publication: August 2020.en
dc.identifier.issn0090-8258en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/29175en
dc.description.abstractBackground: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making traditional coordination of genetic testing by genetic services unsustainable. Consequently alternative models of genetic testing have been developed to improve testing at the initial diagnosis for all eligible women. Method(s): A training module to enable mainstreamed genetic testing by oncology healthcare professionals was developed by genetic health professionals. Oncology healthcare professionals completed questionnaires before and 12 months post-training to assess perceived skills, competence and barriers to their coordinating genetic testing for women with high-grade non-mucinous epithelial ovarian cancer. Genetic health professionals were surveyed 12 months post-training to assess perceived barriers to implementation of mainstreaming. Result(s): 185 oncology healthcare professionals were trained in 42 workshops at 35 Australasian hospitals. Of the 273 tests ordered by oncology healthcare professionals post-training, 241 (93.1%) met national testing guidelines. The number of tests ordered by genetic health professionals reduced significantly (z = 45.0, p = 0.008). Oncology healthcare professionals' perceived barriers to mainstreamed testing decreased from baseline to follow-up (t = 2.39, p = 0.023), particularly perceived skills, knowledge and attitudes. However, only 58% reported either 'always' or 'nearly always' having ordered BRCA testing for eligible patients at 12 months, suggesting oncology healthcare professionals' perceived barriers were not systematically addressed through training. Conclusion(s): Oncology healthcare professionals have demonstrated a willingness to be involved in the provision of genetic testing in a mainstreaming model. If oncology services are to hold responsibility for coordinating genetic testing, their readiness will require understanding of barriers not addressed by training alone to inform future intervention design.Copyright © 2020en
dc.languageEnglishen
dc.languageenen
dc.publisherAcademic Press Inc. (E-mail: apjcs@harcourt.com)en
dc.relation.ispartofGynecologic Oncologyen
dc.subject.meshmedical education-
dc.subject.meshmedical geneticist-
dc.subject.meshoncologist-
dc.subject.meshovary carcinoma-
dc.subject.meshprofessional competence-
dc.subject.meshprofessional knowledge-
dc.subject.meshprogram development-
dc.subject.meshprogram evaluation-
dc.subject.meshworkload-
dc.subject.meshcancer patient-
dc.subject.meshgenetic screening-
dc.subject.meshhealth care personnel-
dc.subject.meshhealth personnel attitude-
dc.subject.meshhealth practitioner-
dc.subject.meshworkshop-
dc.titleThe development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.en
dc.typeArticleen
dc.identifier.affiliationGenetics-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.ygyno.2020.05.001-
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid32451123 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32451123]en
dc.identifier.source2005976299en
dc.identifier.institution(Gleeson) Hunter Family Cancer Service, Newcastle, Australia (Kentwell, James, Scott, Murphy, Antill) Parkville Familial Cancer Clinic, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia (Kentwell) The Royal Women's Hospital, Oncology and Dysplasia, Melbourne, Australia (Meiser, Do, Nevin, Williams, Tucker) Prince of Wales Clinical School, UNSW Sydney, Australia (Taylor) The Cancer Council New South Wales, Sydney and Faculty of Health Science, University of Sydney, Australia (Barlow-Stewart) Sydney Medical School, University of Sydney, Australia (Kirk) Familial Cancer Service, Westmead Hospital, Sydney Medical School, University of Sydney and Centre for Cancer Research, The Westmead Institute for Medical Research, Australia (Scott) Department of Obstetrics and Gynaecology and Department of Medical Biology, University of Melbourne, Australia (Williams, Tucker) Hereditary Cancer Centre, Prince of Wales Hospital, Sydney, Australia (Gamet) Genetic Health Service NZ Northern Hub, Auckland City Hospital, Auckland, New Zealand (Burke) Tasmanian Clinical Genetics Service, Royal Hobart Hospital, Hobart, Australia (Murphy) Bendigo Health Cancer Centre, Bendigo, Australia (Antill) Familial Cancer Centre, Monash Health, Victoria, Australia (Pearn, Pachter) Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Australia (Pachter) School of Medicine, University of Western Australia, Perth, Australia (Ebzery) Genetic Health Queensland, Royal Brisbane and Women's Hospital, Queensland, Australia (Poplawski) Adult Genetics Unit, Royal Adelaide Hospital, Adelaide and School of Medicine, University of Adelaide, Australia (Friedlander) Dept Medical Oncology, Prince of Wales Hospital, Sydney, Australiaen
dc.description.addressM. Gleeson, PO Box 84, Waratah, NSW 2298, Australia. E-mail: Margaret.gleeson@health.nsw.gov.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.subect.keywordsBRCA1/BRCA2 Genetic testing Mainstreaming Ovarian canceren
dc.identifier.authoremailGleeson M.; Margaret.gleeson@health.nsw.gov.auen
dc.description.grantNo: 1078523 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: 1092856 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: RG170040 Organization: *AstraZeneca* Organization No: 100004325 Country: United Kingdomen
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Articles
Show simple item record

Page view(s)

14
checked on Oct 7, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.